baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Vertex Pharmaceuticals/ US92532F1003 /

2024-04-25 9:59:55 PM	Chg. -2.94	Volume	Bid-	Ask-	Market Capitalization	Dividend Y.	P/E Ratio
397.72USD	-0.73%	33,657 Turnover: 13.38 mill.	-Bid Size: -	-Ask Size: -	102.73 bill.USD	-	28.31

GlobeNewswire 04-25 American Kidney Fund Launches National Kidney Health Equity Media Campaign

GlobeNewswire 04-22 TAKE ACTION: The M&A Class Action Firm Launches Legal Inquiry for the Merger - ALPN, LABP, SWAV, FUS...

GlobeNewswire 04-22 CRISPR Therapeutics to Present Oral Presentation at the American Society of Gene & Cell Therapy (ASG...

GlobeNewswire 04-22 SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates INRD, AIRC, ELYM, ALPN

GlobeNewswire 04-22 Kuehn Law Encourages INRD, AIRC, ELYM, and ALPN Investors to Contact Law Firm

GlobeNewswire 04-20 SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ADTH, MODN, ALPN

GlobeNewswire 04-16 SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MGRC, ALPN, NXPL

GlobeNewswire 04-13 SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MODN, ALPN, ELYM, JBT

GlobeNewswire 04-09 American Kidney Fund and Alonzo Mourning Call for More Awareness and Understanding of APOL1-Mediated...

GlobeNewswire 04-03 CRISPR Therapeutics to Present at the Annual Needham Virtual Healthcare Conference

GlobeNewswire 04-01 CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates

GlobeNewswire 04-01 CRISPR Therapeutics to Present at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Me...

GlobeNewswire 03-15 American Kidney Fund Announces 2024 Class of Corporate Members Providing Support in the Fight Agains...

GlobeNewswire 03-13 CRISPR Therapeutics Proposes New Appointment to the Board of Directors

GlobeNewswire 03-13 Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

GlobeNewswire 03-12 MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance

GlobeNewswire 03-12 UNCF 80th Anniversary Gala in Boston Raises More than $750K to Support HBCUs and Students

GlobeNewswire 02-29 New England UNCF “A Mind Is…” Gala to Celebrate UNCF’s 80th Anniversary

GlobeNewswire 02-29 Kidney Month: 31 Day of Action to Equip and Empower People to Fight Kidney Disease

GlobeNewswire 02-28 Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates

GlobeNewswire 02-27 Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financia...

GlobeNewswire 02-26 Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Pamela Stephenson, MPH as...

GlobeNewswire 02-21 CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial...

GlobeNewswire 02-15 CRISPR Therapeutics to Present at the Citi 2024 Virtual Oncology Leadership Summit

GlobeNewswire 02-13 CRISPR Therapeutics Announces $280 Million Registered Direct Offering

Vertex Pharmaceuticals/ US92532F1003 /

If you wish to receive reply to your feedback, please provide your email address.